LIST OF FIGURES
Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Partnerships and Collaborations
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Evolution of Precision Medicine
Figure 5.2 Oncology Precision Medicine over Traditional Cancer Medicine
Figure 5.3 Steps Involved in Developing Oncology Precision Medicines
Figure 5.4 Challenges Associated with Oncology Precision Medicines
Figure 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development
Figure 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Body
Figure 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Region
Figure 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Designation
Figure 6.5 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Molecule
Figure 6.6 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Class
Figure 6.7 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Route of Administration
Figure 6.8 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Dosage Regimen
Figure 6.9 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Patient Population
Figure 6.10 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Figure 6.11 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development and Type of Cancer Targeted
Figure 6.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Stage of Development
Figure 6.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Molecule
Figure 6.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Drug Class
Figure 6.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Figure 6.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of Establishment
Figure 6.17 Oncology Precision Medicine: Distribution of Drug Developers by Company Size
Figure 6.18 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Region)
Figure 6.19 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Country)
Figure 6.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)
Figure 6.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines
Figure 7.1 AstraZeneca: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.2 Roche (Parent Company of Genentech): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.3 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.4 Novartis: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 7.5 Pfizer: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Drug Involved
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Cancer Targeted
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnership and Collaborations: Local and International Agreements
Figure 9.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 10.1 Clinical Trial Analysis: Cumulative Year-wise Trend, 2018-2023
Figure 10.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2018-2023
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2018-2023
Figure 10.6 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2018-2023
Figure 10.8 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 10.9 Clinical Trial Analysis: Distribution by Patient Gender
Figure 10.10 Clinical Trial Analysis: Distribution by Type of Cancer Targeted
Figure 10.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.12 Clinical Trial Analysis: Distribution by Type of Trial Masking
Figure 10.13 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 10.14 Clinical Trial Analysis: Distribution by Type of Intervention
Figure 10.15 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 10.16 Leading Industry Players: Distribution by Number of Clinical Trials
Figure 10.17 Leading Non-Industry Players: Distribution by Number of Clinical Trials
Figure 10.18 Word Cloud Analysis: Emerging Focus Areas
Figure 10.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 10.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 10.21 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 11.1 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development
Figure 11.2 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance
Figure 11.3 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability
Figure 11.4 Oncology Precision Medicine Assay Kits: Distribution by Type of Test
Figure 11.5 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used
Figure 11.6 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection
Figure 11.7 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time
Figure 11.8 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted
Figure 11.9 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted
Figure 11.10 Oncology Precision Medicine Assay Kits: Distribution by End-user
Figure 11.11 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user
Figure 11.12 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user
Figure 11.13 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment
Figure 11.14 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size
Figure 11.15 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)
Figure 11.16 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)
Figure 11.17 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)
Figure 11.18 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model
Figure 11.19 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed
Figure 12.1 Applications of NGS in Oncology Precision Medicine
Figure 12.2 Applications of Nanotechnology in Oncology Precision Medicine
Figure 12.3 Applications of Molecular Imaging Technologies in Oncology Precision Medicine
Figure 12.4 Applications of Omics Technologies in Oncology Precision Medicine
Figure 12.5 Applications of AI in Oncology Precision Medicine
Figure 13.1 Oncology Precision Medicine: Market Drivers
Figure 13.2 Oncology Precision Medicine: Market Restraints
Figure 13.3 Oncology Precision Medicine: Market Opportunities
Figure 13.4 Oncology Precision Medicine: Market Challenges
Figure 14.1 Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.2 Global Oncology Precision Medicine Market, 2023-2035: Conservative Scenario (USD Billion)
Figure 14.3 Global Oncology Precision Medicine Market, 2023-2035: Optimistic Scenario (USD Billion)
Figure 15.1 Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
Figure 15.2 Oncology Precision Medicine Market for Bladder Cancer, 2023-2035 (USD Billion)
Figure 15.3 Oncology Precision Medicine Market for Blood / Hematologic Cancer, 2023-2035 (USD Billion)
Figure 15.4 Oncology Precision Medicine Market for Breast Cancer, 2023-2035 (USD Billion)
Figure 15.5 Oncology Precision Medicine Market for Cervical Cancer, 2023-2035 (USD Billion)
Figure 15.6 Oncology Precision Medicine Market for Gastrointestinal Cancer, 2023-2035 (USD Billion)
Figure 15.7 Oncology Precision Medicine Market for Head and Neck Squamous Cancer, 2023-2035 (USD Billion)
Figure 15.8 Oncology Precision Medicine Market for Lung Cancer, 2023-2035 (USD Billion)
Figure 15.9 Oncology Precision Medicine Market for Skin Cancer, 2023-2035 (USD Billion)
Figure 15.10 Oncology Precision Medicine Market for Other Cancers, 2023-2035 (USD Billion)
Figure 16.1 Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
Figure 16.2 Oncology Precision Medicine Market for Oral, 2023-2035 (USD Billion)
Figure 16.3 Oncology Precision Medicine Market for Intravenous, 2023-2035 (USD Billion)
Figure 16.4 Oncology Precision Medicine Market for Others, 2023-2035 (USD Billion)
Figure 17.1 Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
Figure 17.2 Oncology Precision Medicine Market for Small Molecules, 2023-2035 (USD Billion)
Figure 17.3 Oncology Precision Medicine Market for Biologics, 2023-2035, (USD Billion)
Figure 18.1 Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
Figure 18.2 Oncology Precision Medicine Market for Kinase Inhibitors, 2023-2035 (USD Billion)
Figure 18.3 Oncology Precision Medicine Market for Enzyme Inhibitors,2023-2035 (USD Billion)
Figure 18.4 Oncology Precision Medicine Market for Immune Checkpoint Inhibitors, 2023-2035 (USD Billion)
Figure 18.5 Oncology Precision Medicine Market for Others, 2023-2035 (USD Billion)
Figure 19.1 Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
Figure 19.2 Oncology Precision Medicine Market in North America, 2023-2035 (USD Billion)
Figure 19.3 Oncology Precision Medicine Market in the US, 2023-2035 (USD Billion)
Figure 19.4 Oncology Precision Medicine Market in Canada, 2023-2035 (USD Billion)
Figure 19.5 Oncology Precision Medicine Market in Europe, 2023-2035 (USD Billion)
Figure 19.6 Oncology Precision Medicine Market in France, 2023-2035 (USD Billion)
Figure 19.7 Oncology Precision Medicine Market in Germany, 2023-2035 (USD Billion)
Figure 19.8 Oncology Precision Medicine Market in Italy, 2023-2035 (USD Billion)
Figure 19.9 Oncology Precision Medicine Market in Spain, 2023-2035 (USD Billion)
Figure 19.10 Oncology Precision Medicine Market in UK, 2023-2035 (USD Billion)
Figure 19.11 Oncology Precision Medicine Market in Asia, 2023-2035 (USD Billion)
Figure 19.12 Oncology Precision Medicine Market in China, 2023-2035 (USD Billion)
Figure 19.13 Oncology Precision Medicine Market in Japan, 2023-2035 (USD Billion)
Figure 19.14 Oncology Precision Medicine Market in Korea, 2023-2035 (USD Billion)
Figure 19.15 Oncology Precision Medicine Market in India, 2023-2035 (USD Billion)
Figure 19.16 Oncology Precision Medicine Market in Middle East and North Africa, 2023-2035 (USD Billion)
Figure 19.17 Oncology Precision Medicine Market in UAE, 2023-2035 (USD Billion)
Figure 19.18 Oncology Precision Medicine Market in Israel, 2023-2035 (USD Billion)
Figure 19.19 Oncology Precision Medicine Market in Qatar, 2023-2035 (USD Billion)
Figure 19.20 Oncology Precision Medicine Market in Rest of Middle East and North Africa, 2023-2035 (USD Billion)
Figure 19.21 Oncology Precision Medicine Market in Latin America, 2023-2035 (USD Billion)
Figure 19.22 Oncology Precision Medicine Market in Brazil, 2023-2035 (USD Billion)
Figure 19.23 Oncology Precision Medicine Market in Israel, 2023-2035 (USD Billion)
Figure 19.24 Oncology Precision Medicine Market in Chile, 2023-2035 (USD Billion)
Figure 19.25 Oncology Precision Medicine Market in Rest of Latin America, 2023-2035 (USD Billion)
Figure 20.1 Blockbuster Commercialized Oncology Precision Medicine Market: ADCETRIS® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.2 Blockbuster Commercialized Oncology Precision Medicine Market: Alecensa® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.3 Blockbuster Commercialized Oncology Precision Medicine Market: ALUNBRIG® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.4 Blockbuster Commercialized Oncology Precision Medicine Market: Avastin® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.5 Blockbuster Commercialized Oncology Precision Medicine Market: Ayvakit® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.6 Blockbuster Commercialized Oncology Precision Medicine Market: Braftovi®+ Mektovi® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.7 Blockbuster Commercialized Oncology Precision Medicine Market: BRUKINSA® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.8 Blockbuster Commercialized Oncology Precision Medicine Market: CALQUENCE® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.9 Blockbuster Commercialized Oncology Precision Medicine Market: DARZALEX® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.10 Blockbuster Commercialized Oncology Precision Medicine Market: Elunate® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.11 Blockbuster Commercialized Oncology Precision Medicine Market: Empliciti® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.12 Blockbuster Commercialized Oncology Precision Medicine Market: Enhertu® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.13 Blockbuster Commercialized Oncology Precision Medicine Market: IBRANCE® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.14 Blockbuster Commercialized Oncology Precision Medicine Market: ICLUSIG® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.15 Blockbuster Commercialized Oncology Precision Medicine Market: IMBRUVICA® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.16 Blockbuster Commercialized Oncology Precision Medicine Market: IMFINZI® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.17 Blockbuster Commercialized Oncology Precision Medicine Market: INLYTA® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.18 Blockbuster Commercialized Oncology Precision Medicine Market: Keytruda® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.19 Blockbuster Commercialized Oncology Precision Medicine Market: Kadcyla® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.20 Blockbuster Commercialized Oncology Precision Medicine Market: LENVIMA® / KISPLYX® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.21 Blockbuster Commercialized Oncology Precision Medicine Market: Lumakras® / Lumykras® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.22 Blockbuster Commercialized Oncology Precision Medicine Market: Mekinist® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.23 Blockbuster Commercialized Oncology Precision Medicine Market: NERLYNX® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.24 Blockbuster Commercialized Oncology Precision Medicine Market: NINLARO® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.25 Blockbuster Commercialized Oncology Precision Medicine Market: Opdivo® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.26 Blockbuster Commercialized Oncology Precision Medicine Market: Padcev® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.27 Blockbuster Commercialized Oncology Precision Medicine Market: Piqray® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.28 Blockbuster Commercialized Oncology Precision Medicine Market: Sprycel® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.29 Blockbuster Commercialized Oncology Precision Medicine Market: Tabrecta® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.30 Blockbuster Commercialized Oncology Precision Medicine Market: Tagrisso® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.31 Blockbuster Commercialized Oncology Precision Medicine Market: Tasigna® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.32 Blockbuster Commercialized Oncology Precision Medicine Market: Tecentriq® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.33 Blockbuster Commercialized Oncology Precision Medicine Market: VENCLEXTA® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.34 Blockbuster Commercialized Oncology Precision Medicine Market: Verzenio® / Verzenios Sales Forecast, 2023-2035 (USD Billion)
Figure 20.35 Blockbuster Commercialized Oncology Precision Medicine Market: Xospata® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.36 Blockbuster Commercialized Oncology Precision Medicine Market: XTANDI® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.37 Blockbuster Commercialized Oncology Precision Medicine Market: ZEJULA® Sales Forecast, 2023-2035 (USD Billion)
Figure 20.38 NDA-filed Oncology Precision Medicine Market: Apatinib / Rivoceranib Sales Forecast, 2024-2035 (USD Billion)
Figure 20.39 NDA-filed Oncology Precision Medicine Market: Elunate® Sales Forecast, 2025-2035 (USD Billion)
Figure 20.40 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Sales Forecast, 2030-2035 (USD Billion)
Figure 20.41 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Regional Sales Forecast, 2030-2035 (USD Billion)
Figure 20.42 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Sales Forecast, 2030-2035 (USD Billion)
Figure 20.43 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Regional Sales Forecast, 2030-2035 (USD Billion)
Figure 20.44 Phase III Oncology Precision Medicine Market: Elunate® Sales Forecast, 2025-2035 (USD Billion)
Figure 20.45 Phase III Oncology Precision Medicine Market: Elunate® Sales Forecast by Type of Cancer Targeted, 2025-2035 (USD Billion)
Figure 20.46 Phase III Oncology Precision Medicine Market: Elunate® Regional Sales Forecast, 2025-2035 (USD Billion)
Figure 20.47 Phase III Oncology Precision Medicine Market: ORPATHYS® Sales Forecast, 2028-2035 (USD Billion)
Figure 20.48 Phase III Oncology Precision Medicine Market: ORPATHYS® Regional Sales Forecast, 2028-2035 (USD Billion)
Figure 20.49 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast, 2025-2035 (USD Billion)
Figure 20.50 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast by Type of Cancer Targeted, 2025-2035 (USD Billion)
Figure 20.51 Phase III Oncology Precision Medicine Market: Pyrotinib Regional Sales Forecast, 2025-2035 (USD Billion)
Figure 20.52 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Sales Forecast, 2025-2035 (USD Billion)
Figure 20.53 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Regional Sales Forecast, 2025-2035 (USD Billion)
Figure 20.54 Phase III Oncology Precision Medicine Market: ZOLINZA® Sales Forecast, 2024-2035 (USD Billion)
Figure 20.55 Phase III Oncology Precision Medicine Market: ZOLINZA® Regional Sales Forecast, 2024-2035 (USD Billion)
Figure 21.1 Oncology Precision Medicine Market: Distribution by Leading Drug Developers (based on sales of oncology precision medicines in the year 2022 (USD Billion))
Figure 22.2 Conclusion: Market Landscape
Figure 22.3 Conclusion: Partnerships and Collaborations
Figure 22.4 Conclusion: Clinical Trial Analysis
Figure 22.5 Conclusion: Case Study Oncology Precision Medicine Assay Kits
Figure 22.6 Conclusion: Market Forecast and Opportunity Analysis
LIST OF TABLES
Table 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Developer, Brand, Stage of Development, Approval Body and Approval Region
Table 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Drug Designation
Table 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Molecule, Drug Class, Route of Administration, Dosage Regimen and Patient Population
Table 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Cancer Targeted
Table 6.5 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Developer and Stage of Development
Table 6.6 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Molecule and Drug Class
Table 6.7 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Cancer Targeted
Table 6.8 Oncology Precision Medicine: List of Developers
Table 7.1 Oncology Precision Medicine: List of Companies Profiled
Table 7.2 AstraZeneca: Company Snapshot
Table 7.3 AstraZeneca: Oncology Precision Medicine Portfolio
Table 7.4 AstraZeneca: Recent Developments and Future Outlook
Table 7.5 Genentech: Company Snapshot
Table 7.6 Genentech: Oncology Precision Medicine Portfolio
Table 7.7 Jiangsu Hengrui Pharmaceuticals: Company Snapshot
Table 7.8 Jiangsu Hengrui Pharmaceuticals: Oncology Precision Medicine Portfolio
Table 7.9 Johnson & Johnson Innovative Medicine: Company Snapshot
Table 7.10 Johnson & Johnson Innovative Medicine: Oncology Precision Medicine Portfolio
Table 7.11 Johnson & Johnson Innovative Medicine: Recent Developments and Future Outlook
Table 7.12 Novartis: Company Snapshot
Table 7.13 Novartis: Oncology Precision Medicine Portfolio
Table 7.14 Novartis: Recent Developments and Future Outlook
Table 7.15 Pfizer: Company Snapshot
Table 7.16 Pfizer: Oncology Precision Medicine Portfolio
Table 7.17 Pfizer: Recent Developments and Future Outlook
Table 7.18 SpringWorks Therapeutics: Company Snapshot
Table 7.19 SpringWorks Therapeutics: Oncology Precision Medicine Portfolio
Table 7.20 SpringWorks Therapeutics: Recent Developments and Future Outlook
Table 8.1 Oncology Precision Medicine: List of Companies Profiled
Table 8.2 Company Profile: AbbVie
Table 8.3 Company Profile: Anticancer Biosciences
Table 8.4 Company Profile: Astellas Pharma
Table 8.5 Company Profile: Bayer
Table 8.6 Company Profile: Blueprint Medicines
Table 8.7 Company Profile: Bristol Myers Squibb
Table 8.8 Company Profile: Eli Lilly
Table 8.9 Company Profile: Erasca
Table 8.10 Company Profile: GlaxoSmithKline
Table 8.11 Company Profile: Hutchmed
Table 8.12 Company Profile: IDEAYA Biosciences
Table 8.13 Company Profile: Merck
Table 8.14 Company Profile: Repare Therapeutics
Table 8.15 Company Profile: Roche
Table 8.16 Company Profile: Seagen
Table 8.17 Company Profile: Takeda Pharmaceutical
Table 8.18 Company Profile: VERAXA Biotech GmbH
Table 8.19 Company Profile: VRise Therapeutics
Table 9.1 Oncology Precision Medicine: List of Partnerships and Collaborations, 2018-2023
Table 9.2 Partnerships and Collaborations: Information on Drug Involved and Type of Cancer Targeted
Table 9.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
Table 11.1 Oncology Precision Medicine Assay Kits: Information on Developer, Stage of Development, Regulatory Certification / Compliance and Regional Availability
Table 11.2 Oncology Precision Medicine Assay Kits: Information on Type of Test, Type of Sample, Principle of Biomarker Detection and Turn-around Time
Table 11.3 Oncology Precision Medicine Assay Kits: Information on Type of Cancer Targeted
Table 11.4 Oncology Precision Medicine Assay Kits: Information on End-user
Table 11.5 List of Oncology Precision Medicine Assay Kit Developers
Table 21.1 List of Leading Oncology Precision Medicine Developers
Table 23.1 Allarity Therapeutics: Company Snapshot
Table 23.2 Elephas: Company Snapshot
Table 24.1 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development
Table 24.2 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Body
Table 24.3 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Region
Table 24.4 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Designation
Table 24.5 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Molecule
Table 24.6 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Class
Table 24.7 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Route of Administration
Table 24.8 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Dosage Regimen
Table 24.9 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Patient Population
Table 24.10 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Table 24.11 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development and Type of Cancer Targeted
Table 24.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Stage of Development
Table 24.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Molecule
Table 24.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Drug Class
Table 24.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
Table 24.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of Establishment
Table 24.17 Oncology Precision Medicine: Distribution of Drug Developers by Company Size
Table 24.18 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Region)
Table 24.19 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Country)
Table 24.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)
Table 24.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines
Table 24.22 AstraZeneca: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 24.23 Roche (Parent Company of Genentech): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 24.24 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 24.25 Novartis: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 24.26 Pfizer: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 24.27 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023
Table 24.28 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023
Table 24.30 Partnerships and Collaborations: Distribution by Type of Partner
Table 24.31 Partnerships and Collaborations: Distribution by Drug Involved
Table 24.32 Partnerships and Collaborations: Distribution by Type of Cancer Targeted
Table 24.33 Most Active Players: Distribution by Number of Partnerships
Table 24.34 Partnership and Collaborations: Local and International Agreements
Table 24.35 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 24.36 Clinical Trial Analysis: Cumulative Year-wise Trend, 2018-2023
Table 24.37 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2018-2023
Table 24.38 Clinical Trial Analysis: Distribution by Trial Phase
Table 24.39 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Table 24.40 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2018-2023
Table 24.41 Clinical Trial Analysis: Distribution by Trial Status
Table 24.42 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2018-2023
Table 24.43 Clinical Trial Analysis: Distribution by Target Patient Population
Table 24.44 Clinical Trial Analysis: Distribution by Patient Gender
Table 24.45 Clinical Trial Analysis: Distribution by Type of Cancer Targeted
Table 24.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 24.47 Clinical Trial Analysis: Distribution by Type of Trial Masking
Table 24.48 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 24.49 Clinical Trial Analysis: Distribution by Type of Intervention
Table 24.50 Clinical Trial Analysis: Distribution by Trial Purpose
Table 24.51 Leading Industry Players: Distribution by Number of Clinical Trials
Table 24.52 Leading Non-Industry Players: Distribution by Number of Clinical Trials
Table 24.53 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 24.54 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Table 24.55 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 24.56 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development
Table 24.57 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance
Table 24.58 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability
Table 24.59 Oncology Precision Medicine Assay Kits: Distribution by Type of Test
Table 24.60 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used
Table 24.61 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection
Table 24.62 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time
Table 24.63 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted
Table 24.64 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted
Table 24.65 Oncology Precision Medicine Assay Kits: Distribution by End-user
Table 24.66 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user
Table 24.67 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user
Table 24.68 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment
Table 24.69 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size
Table 24.70 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)
Table 24.71 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)
Table 24.72 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)
Table 24.73 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model
Table 24.74 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed
Table 24.75 Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 24.76 Global Oncology Precision Medicine Market, 2023-2035: Conservative Scenario (USD Billion)
Table 24.77 Global Oncology Precision Medicine Market, 2023-2035: Optimistic Scenario (USD Billion)
Table 24.78 Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
Table 24.79 Oncology Precision Medicine Market for Bladder Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.80 Oncology Precision Medicine Market for Blood / Hematologic Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.81 Oncology Precision Medicine Market for Breast Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.82 Oncology Precision Medicine Market for Cervical Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.83 Oncology Precision Medicine Market for Gastrointestinal Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.84 Oncology Precision Medicine Market for Head and Neck Squamous Cell Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.85 Oncology Precision Medicine Market for Lung Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.86 Oncology Precision Medicine Market for Skin Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.87 Oncology Precision Medicine Market for Other Cancers, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.88 Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
Table 24.89 Oncology Precision Medicine Market for Oral, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.90 Oncology Precision Medicine Market for Intravenous, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.91 Oncology Precision Medicine Market for Others, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.92 Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
Table 24.93 Oncology Precision Medicine Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.94 Oncology Precision Medicine Market for Biologics, Conservative, Base and Optimistic Scenarios, 2023-2035, (USD Billion)
Table 24.95 Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
Table 24.96 Oncology Precision Medicine Market for Kinase Inhibitors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.97 Oncology Precision Medicine Market for Enzyme Inhibitors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.98 Oncology Precision Medicine Market for Immune Checkpoint Inhibitors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.99 Oncology Precision Medicine Market for Others, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.100 Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
Table 24.101 Oncology Precision Medicine Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.102 Oncology Precision Medicine Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.103 Oncology Precision Medicine Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.104 Oncology Precision Medicine Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.105 Oncology Precision Medicine Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.106 Oncology Precision Medicine Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.107 Oncology Precision Medicine Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.108 Oncology Precision Medicine Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.109 Oncology Precision Medicine Market in UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.110 Oncology Precision Medicine Market in Asia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.111 Oncology Precision Medicine Market in China, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.112 Oncology Precision Medicine Market in Japan, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.113 Oncology Precision Medicine Market in Korea, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.114 Oncology Precision Medicine Market in India, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.115 Oncology Precision Medicine Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.116 Oncology Precision Medicine Market in UAE, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.117 Oncology Precision Medicine Market in Israel, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.118 Oncology Precision Medicine Market in Qatar, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.119 Oncology Precision Medicine Market in Rest of Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.120 Oncology Precision Medicine Market in Latin America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.121 Oncology Precision Medicine Market in Brazil, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.122 Oncology Precision Medicine Market in Argentina, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.123 Oncology Precision Medicine Market in Chile, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.124 Oncology Precision Medicine Market in Rest of Latin America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.125 Blockbuster Commercialized Oncology Precision Medicine Market: ADCETRIS® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.126 Blockbuster Commercialized Oncology Precision Medicine Market: Alecensa® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.127 Blockbuster Commercialized Oncology Precision Medicine Market: ALUNBRIG® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.128 Blockbuster Commercialized Oncology Precision Medicine Market: Avastin® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.129 Blockbuster Commercialized Oncology Precision Medicine Market: Ayvakit® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.130 Blockbuster Commercialized Oncology Precision Medicine Market: Braftovi®+ Mektovi® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.131 Blockbuster Commercialized Oncology Precision Medicine Market: BRUKINSA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.132 Blockbuster Commercialized Oncology Precision Medicine Market: CALQUENCE® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.133 Blockbuster Commercialized Oncology Precision Medicine Market: DARZALEX® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.134 Blockbuster Commercialized Oncology Precision Medicine Market: Elunate® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.135 Blockbuster Commercialized Oncology Precision Medicine Market: Empliciti® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.136 Blockbuster Commercialized Oncology Precision Medicine Market: Enhertu® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.137 Blockbuster Commercialized Oncology Precision Medicine Market: IBRANCE® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.138 Blockbuster Commercialized Oncology Precision Medicine Market: ICLUSIG® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.139 Blockbuster Commercialized Oncology Precision Medicine Market: IMBRUVICA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.140 Blockbuster Commercialized Oncology Precision Medicine Market: IMFINZI® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.141 Blockbuster Commercialized Oncology Precision Medicine Market: INLYTA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.142 Blockbuster Commercialized Oncology Precision Medicine Market: Keytruda® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.143 Blockbuster Commercialized Oncology Precision Medicine Market: Kadcyla® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.144 Blockbuster Commercialized Oncology Precision Medicine Market: LENVIMA® / KISPLYX® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.145 Blockbuster Commercialized Oncology Precision Medicine Market: Lumakras® / Lumykras® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.146 Blockbuster Commercialized Oncology Precision Medicine Market: Mekinist® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.147 Blockbuster Commercialized Oncology Precision Medicine Market: NERLYNX® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.148 Blockbuster Commercialized Oncology Precision Medicine Market: NINLARO® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.149 Blockbuster Commercialized Oncology Precision Medicine Market: Opdivo® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.150 Blockbuster Commercialized Oncology Precision Medicine Market: Padcev® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.151 Blockbuster Commercialized Oncology Precision Medicine Market: Piqray® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.152 Blockbuster Commercialized Oncology Precision Medicine Market: Sprycel® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.153 Blockbuster Commercialized Oncology Precision Medicine Market: Tabrecta® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.154 Blockbuster Commercialized Oncology Precision Medicine Market: Tagrisso® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.155 Blockbuster Commercialized Oncology Precision Medicine Market: Tasigna® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.156 Blockbuster Commercialized Oncology Precision Medicine Market: Tecentriq® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.157 Blockbuster Commercialized Oncology Precision Medicine Market: VENCLEXTA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.158 Blockbuster Commercialized Oncology Precision Medicine Market: Verzenio® / Verzenios Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.159 Blockbuster Commercialized Oncology Precision Medicine Market: Xospata® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.160 Blockbuster Commercialized Oncology Precision Medicine Market: XTANDI® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.161 Blockbuster Commercialized Oncology Precision Medicine Market: ZEJULA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 24.162 NDA-filed Oncology Precision Medicine Market: Apatinib / Rivoceranib Sales Forecast, Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Billion)
Table 24.163 NDA-filed Oncology Precision Medicine Market: Elunate® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.164 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)
Table 24.165 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)
Table 24.166 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)
Table 24.167 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)
Table 24.168 Phase III Oncology Precision Medicine Market: Elunate® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.169 Phase III Oncology Precision Medicine Market: Elunate® Sales Forecast by Type of Cancer Targeted, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.170 Phase III Oncology Precision Medicine Market: Elunate® Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.171 Phase III Oncology Precision Medicine Market: ORPATHYS® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2028-2035 (USD Billion)
Table 24.172 Phase III Oncology Precision Medicine Market: ORPATHYS® Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2028-2035 (USD Billion)
Table 24.173 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.174 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast by Type of Cancer Targeted, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.175 Phase III Oncology Precision Medicine Market: Pyrotinib Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.176 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.177 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.178 Phase III Oncology Precision Medicine Market: ZOLINZA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.179 Phase III Oncology Precision Medicine Market: ZOLINZA® Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
Table 24.180 Oncology Precision Medicine Market: Distribution by Leading Drug Developers (based on sales of oncology precision medicines in the year 2022 (USD Billion))